Vocabria

Generic name: cabotegravir

Used for: Short-term HIV treatment (before or instead of Cabenuva shots) · Short-term PrEP against HIV (before or instead of Apretude shots) · 1 more

How do you pay?

How to pay the least

Ask for the cash price

Vocabria

We didn’t find one.

  1. Ask your pharmacy for Vocabria’s cash price, and one or two other pharmacies too.

Compare every option

Question
Brand nameVocabria
Authorized genericcabotegravir
Regular genericcabotegravir
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Vocabria?
The original
–
–

Brand nameNo maker’s card

We didn’t find a savings card or cash price from Vocabria’s maker. Ask the pharmacy for Vocabria’s cash price. With insurance, ask what your plan charges.

Authorized genericNot sold

There isn’t one. An authorized generic is Vocabria itself, from the same company, sold without the brand name, and usually for less. For now Vocabria is the only choice; ask the pharmacy for its cash price, or your plan what it charges.

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, ask the pharmacy for Vocabria’s cash price, or your plan what it charges.

What it’s used for

What the FDA label says

HIV-1 Treatment: VOCABRIA is an HIV-1 integrase strand transfer inhibitor (INSTI) indicated in combination with EDURANT (rilpivirine) for short-term treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.

HIV-1 Pre-Exposure Prophylaxis: VOCABRIA is indicated for short-term pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating VOCABRIA for HIV-1 PrEP.

VOCABRIA may be used as:

  • oral lead-in to assess the tolerability of cabotegravir prior to administration of CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension) for HIV-1 treatment or APRETUDE (cabotegravir extended-release injectable suspension) for HIV-1 PrEP.
  • oral therapy for patients who will miss planned injection dosing with CABENUVA for HIV-1 treatment or APRETUDE for HIV-1 PrEP.

Source: the FDA label for Vocabria (ViiV Healthcare Company), April 11, 2025. Full label on DailyMed 

Good to know

Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/vocabria/